Talk:Scott W. Lowe

Improving Dr. Scott W. Lowe's Article

I've been working on improving the article for overall organization and to add more detail to the article. It's disappointing there are not more references to support his work but I did my best with the content available on the internet. I've added references for the new content as well as the existing content. Would anyone be open to review the updates in my sandbox  ? Here is the [comparison] with the current article. Let me know if you have any questions!--Chefmikesf (talk) 23:53, 18 May 2020 (UTC)

Article Edits

Location: Infobox 1. Please add this image to the Infobox Add | image = Cancer Biologist Scott Lowe Location: Lead Paragraph 2. Please update the lead paragraph. Is update makes the lead paragraph read better and updates Dr. Lowe's current roll at Memorial Sloan Kettering. Current content: Scott William Lowe (born October 4, 1963) is the Chair of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Cancer Center and Howard Hughes Medical Institute Investigator. Proposed Content: Scott William Lowe (born October 4, 1963) is Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. Location: Early Education 3. Please add two words to the early education section for the readability of the section. 1. Add the word the after the word at in sentence two 2. Remove the word Working from sentence three Location: Career 4. Please add as the first sentence to the Career section While at MIT, he showed that the tumor suppressor p53 is required for the cell death program that occurs in response to cytotoxic agents such as ionizing radiation and DNA-damaging chemotherapies. Location: Career 5. Request five helps update the Career section with an accurate account of his work at the Cold Spring Harbor Laboratory on p53. Current content: He moved from MIT to Cold Spring Harbor Laboratory, starting his own laboratory as an assistant professor there in 1995 and continuing his work on p53. A key outcome of this research was experimental validation of oncogene-induced senescence. Proposed Content: He moved from MIT to Cold Spring Harbor Laboratory, starting his own laboratory as a Cold Spring Harbor Laboratory Fellow in 1995 and continuing his work on p53. A key outcome of this research was the discovery of a process known as oncogene-induced senescence, which is now a well-established tumor suppressive program. Location: Career 6. Please copy-edit for grammar Copy edit "His laboratory's" to "His laboratories" for proper grammar Location: Career 7. Current Content: He eventually became Deputy Director of the Cancer Center. Much of his work has focused on tumor suppressor genes, and their relation to drug resistance after chemotherapy treatment. Proposed Content: He eventually became Deputy Director of the CSHL Cancer Center. Much of his work has focused on the biological action of tumor suppressor genes, and the consequences of their mutation. Location: Career 8. Current Content: He moved to Sloan Kettering in 2011 to lead the department of Cancer Biology and Genetics. He has been an HHMI Investigator since 2005. In 2017, Dr. Lowe was elected to the United States National Academy of Sciences. In 2019, Dr. Lowe was elected to the National Academy of Medicine. Proposed Content: He is also known for using genome-editing tools such as CRISPR to create valuable mouse models of different cancers. He moved to Memorial Sloan Kettering in 2011 to lead the Cancer Biology and Genetics Program in the Sloan Kettering Institute, where he discovered mechanisms whereby senescence inducing therapies promote cancer cell immune surveillance. In 2015, Lowe continued his use of RNAi to study the tumor suppressor APC in colorectal cancer. He has been an HHMI Investigator since 2005. In 2017, Dr. Lowe was elected to the United States National Academy of Sciences. In 2019, Dr. Lowe was elected to the National Academy of Medicine. References

--Chefmikesf (talk) 18:57, 3 August 2020 (UTC)

 Done Parts 1-7. I'll leave part 8 for someone else because I'm a little confused by it and what references support those statements. Also, is he no longer funded by HHMI? Natureium (talk) 21:35, 4 August 2020 (UTC)

Natureium,Thank you for your help on this. I see what you mean about number 8, so updated the references to match the content. Could you take one more look? I will get back to you about HHMI.--Chefmikesf (talk) 00:53, 6 August 2020 (UTC)

Chefmikesf, I've taken a look at #8 and I must say I'm a bit confused too. For example: "He is also known for using genome-editing tools such as CRISPR to create valuable mouse models of different cancers.", but apparently neither source mentions genome-editing nor CRISPR as such. May I suggest providing inline sourcing for each of the three sentences? GregorB (talk) 21:14, 7 October 2020 (UTC)

Chefmikesf, this looks good to me! I hope I'll make a more thorough pass tomorrow; in the meantime, could you just tweak "recently" per MOS:RECENTLY? GregorB (talk) 20:31, 14 October 2020 (UTC)

GregorB Updated! Let me know if you have anymore feedback.--Chefmikesf (talk) 16:54, 15 October 2020 (UTC)

Chefmikesf, everything checks out fine, except that "Ruscetti nature/cell" is unclear to me, so I suppose something needs to be done here (wikilinking, rephrasing, or perhaps removing it altogether?). GregorB (talk)

GregorB, I wanted to find another source for the statement but the only one I can find is the peer reviewed journal. What are your thoughts? See here: https://pubmed.ncbi.nlm.nih.gov/32234521/--Chefmikesf (talk) 18:59, 20 October 2020 (UTC)

Oh, I get it now, it's Ruscetti et al. in Cell. That's it then. GregorB (talk) 19:22, 20 October 2020 (UTC)

 Done part 8. GregorB (talk) 19:28, 20 October 2020 (UTC)